Stifel analyst Dylan Van Haaften initiated coverage of Medacta Group with a Buy rating and CHF 154 price target. The analyst forecasts above market growth and net market share gains for all three companies in the European orthopaedics market. Within the firm’s coverage, Medacta is its most preferred given its superior product portfolio and attractive valuation and Smith & Nephew is its least preferred given Stifel believes its turnaround is already factored in to its valuation.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>